Patents Assigned to GLAXOSMITHKILINE BIOLOGICALS S.A.
  • Publication number: 20170065696
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Application
    Filed: January 23, 2015
    Publication date: March 9, 2017
    Applicant: GLAXOSMITHKILINE BIOLOGICALS S.A.
    Inventors: Rhea COLER, Steven REED, Yves LOBET
  • Publication number: 20150231224
    Abstract: The present invention is directed to methods of preventing reactivation of active and latent M. tuberculosis infections by administering a pharmaceutical composition comprising a nucleic acid encoding a Mtb72f fusion protein, or a Mtb72f fusion protein or an immunogenic fragment thereof, for example together with an adjuvant. The Mtb72f nucleic acid or fusion protein can be administered with one or more chemotherapeutic agents effective against a M. tuberculosis infection. The methods also provide for shortening the time course of a chemotherapeutic regimen against a M. tuberculosis infection.
    Type: Application
    Filed: January 23, 2015
    Publication date: August 20, 2015
    Applicant: GLAXOSMITHKILINE BIOLOGICALS S.A.
    Inventors: Rhea COLER, Steven REED, Yves LOBET